These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

748 related items for PubMed ID: 24342246

  • 1. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH, Kantele JM, Herzog C, Kantele A.
    Vaccine; 2014 Jan 23; 32(5):544-51. PubMed ID: 24342246
    [Abstract] [Full Text] [Related]

  • 2. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.
    Vaccine; 2015 Jan 09; 33(3):451-8. PubMed ID: 25433216
    [Abstract] [Full Text] [Related]

  • 3. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
    Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM.
    Vaccine; 2012 Nov 26; 30(50):7238-45. PubMed ID: 23084770
    [Abstract] [Full Text] [Related]

  • 4. Cross-reactive immune response induced by the Vi capsular polysaccharide typhoid vaccine against Salmonella Paratyphi strains.
    Pakkanen SH, Kantele JM, Kantele A.
    Scand J Immunol; 2014 Mar 26; 79(3):222-9. PubMed ID: 24383914
    [Abstract] [Full Text] [Related]

  • 5. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination.
    Pakkanen SH, Kantele JM, Kantele A.
    Vaccine; 2012 Sep 14; 30(42):6047-53. PubMed ID: 22858557
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A, Pakkanen SH, Karttunen R, Kantele JM.
    PLoS One; 2013 Sep 14; 8(4):e60583. PubMed ID: 23593253
    [Abstract] [Full Text] [Related]

  • 7. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
    Pakkanen SH, Kantele JM, Rombo L, Kantele A.
    Scand J Immunol; 2017 Oct 14; 86(4):207-215. PubMed ID: 28675263
    [Abstract] [Full Text] [Related]

  • 8. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.
    J Infect Dis; 2004 Aug 01; 190(3):565-70. PubMed ID: 15243933
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh.
    Bhuiyan TR, Choudhury FK, Khanam F, Saha A, Sayeed MA, Salma U, Lundgren A, Sack DA, Svennerholm AM, Qadri F.
    Vaccine; 2014 Feb 19; 32(9):1055-60. PubMed ID: 24440210
    [Abstract] [Full Text] [Related]

  • 10. Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans.
    Wahid R, Fresnay S, Levine MM, Sztein MB.
    Mucosal Immunol; 2015 Nov 19; 8(6):1349-59. PubMed ID: 25872480
    [Abstract] [Full Text] [Related]

  • 11. Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.
    Wahid R, Fresnay S, Levine MM, Sztein MB.
    Clin Immunol; 2016 Dec 19; 173():87-95. PubMed ID: 27634430
    [Abstract] [Full Text] [Related]

  • 12. Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.
    Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y.
    Front Cell Infect Microbiol; 2017 Dec 19; 7():135. PubMed ID: 28484685
    [Abstract] [Full Text] [Related]

  • 13. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.
    Clin Vaccine Immunol; 2007 Oct 19; 14(10):1285-95. PubMed ID: 17687110
    [Abstract] [Full Text] [Related]

  • 14. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY, Noriega FR, Galen JE, Barry E, Levine MM.
    Infect Immun; 2000 Aug 19; 68(8):4647-52. PubMed ID: 10899868
    [Abstract] [Full Text] [Related]

  • 15. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, Turner D, Tizard I.
    Vaccine; 2017 Dec 18; 35(51):7121-7126. PubMed ID: 29150208
    [Abstract] [Full Text] [Related]

  • 16. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN, Osorio M, Takeda K, Stibitz S, Kopecko DJ.
    Clin Vaccine Immunol; 2017 Dec 18; 24(12):. PubMed ID: 29046309
    [Abstract] [Full Text] [Related]

  • 17. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine.
    Salerno-Goncalves R, Pasetti MF, Sztein MB.
    J Immunol; 2002 Aug 15; 169(4):2196-203. PubMed ID: 12165550
    [Abstract] [Full Text] [Related]

  • 18. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.
    Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB.
    Clin Vaccine Immunol; 2012 Jun 15; 19(6):825-34. PubMed ID: 22492745
    [Abstract] [Full Text] [Related]

  • 19. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N, Kothari S, Choi YJ, Dey A, Briles DE, Rhee DK, Carbis R.
    Vaccine; 2015 Feb 04; 33(6):783-8. PubMed ID: 25545593
    [Abstract] [Full Text] [Related]

  • 20. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.
    PLoS Negl Trop Dis; 2016 Aug 04; 10(8):e0004926. PubMed ID: 27533046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.